Introduction: Sepsis is a major cause of mortality and there have been many patient safety initiatives to improve the outcome such as 'Think Sepsis' and 'Sepsis 6'. It is essential to consider mimics of sepsis in those presenting with fever, particularly when there is no improvement despite antimicrobials. Macrophage activation syndrome (MAS) is a complication of uncontrolled inflammation from underlying connective tissue disease resulting in a sepsis-like condition. Delay to the detection and treatment of this condition can also result in significant morbidity and mortality. Case description: We report a 28-year-old female presenting with shortness of breath, chest pain, bilateral leg swelling and fevers. Relevant past medical history included a recent diagnosis of Graves' disease for which she had been commenced on carbimazole. On presentation CRP 53 mg/ L and d-dimer 14100, chest X-ray; cardiomegally and bilateral pleural effusions, CT thoracic aorta angiogram; large pericardial effusion with maximum depth 5.9cm and compression of the cardiac chambers. Echocardiogram; preserved ejection fraction of 55-60%. The patient was commenced on intravenous antibiotics, furosemide and pericardial drain removed1.5L. The patient was referred to the rheumatology team on day 10. She reported episodic arthralgia, recurrent mouth ulcers, anaemia; with no evidence of haemolysis and pericardial effusion (serositis). Serology; ANA 1:1280 fine speckled pattern, dsDNA > 200, ENA positive (RNP and Smith antibodies) and low complement; C3 (0.35) and C4 (0.005), ferritin 1400, CRP 40 and ESR 62; consistent with a diagnosis of systemic lupus erythematosus (SLE). The patient was pulsed with IV methylprednisolone 500mg onDay 13 and started on prednisolone 40mg and azathioprine. Day 16; the patient developed a new pyrexia and profound hypotension resulting in admission to intensive care unit for inotropic support and escalation of antibiotics. Bedside echo revealed a small volume pericardial fluid; no tamponade, but significant new biventricular failure. Repeat ferritin was 8489, Triglycerides 5.5, LDH 331. The patient had persistent fevers and blood dyscrasias consistent with macrophage activation syndrome (MAS) with lupus myocarditis. The patient was pulsed with a further two doses of IV methylprednisolone 750mg and commenced on ciclosporin 3mg/kg. Day 18; the patient became increasingly tachycardic with increasing oxygen demands and a worsening metabolic acidosis despite renal replacement therapy. Based on the rapidity of deterioration, and lack of response to intervention the patient was transferred for extracorporeal membrane oxygenation(ECMO). Discussion:This case was of interest due to the diagnostic difficulties the team faced as an underlying autoimmune condition was not initially considered. Distinguishing the need for antibiotics versus immunosuppression can be daunting for general medical teams. This case highlights the importance of involving rheumatology early in the course of a patient presenting with fever not responding to conventionaltherapies. Lupus myocarditis was confirmed by cardiac biopsy after the patient went into cardiogenic shock with a LVEF 10% due to lupus myocarditis requiring ECMO support showing the severity of disease activity. The use of ECMO remains rare in our practice and there are only five centres within the UK offering this service. The patienthasmade anexcellent responseto treatment and iswell maintained on mycophenolate mofetil and hydroxychloroquine; most recent echocardiogram May 2018 shows resolved effusion with normal biventricular size, ejectionfraction 50 to 55%. Key learning points: MAS secondary to underlying rheumatic and connective tissuedisease canpresent with fever and features that mimic sepsis. An awareness of MAS is needed as early diagnosis and prompt initial treatment are both key factors for a favourable outcome. This case resulted in a change to clinical practice. A Trust-wide guideline on the management of MAS has now been produced to guide teams on the management of MAS in the patient with sepsis who is not improving. This case also shows the importance of collaborative team working (physicians, ICU, tertiary centre).
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SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS WITH MULTI-ORGAN FAILURE IN A TEENAGER
Hannah Law 1 , Alison Kelly 2 , and Lisa Teoh 1 1 Rheumatology, Torbay and South Devon Foundation Trust, Torquay, United Kingdom, and 2 Rheumatology, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom Introduction: Systemic onset juvenile idiopathic arthritis (JIA) is an often severe and potentially life-threatening subtype of chronic arthritis starting under the age of 16 years. It is characterised by fevers, rash and arthritis, although this may not be apparent until later in the disease course, which can add difficulty to making the diagnosis. We present a case of systemic onset JIA with multi-organ impairment to showcase its mimicry of other diseases and highlight importance of awareness Case description: A 15-year-old girl presented with a 7 day history of fever, cough, sore neck, enlarged lymph nodes and widespread macular rash. She had been started on penicillin in the community for presumed scarlet fever, but was hospitalised due to worsening symptoms. Differential diagnoses discussed were lymphadenitis and EBV, due to ongoing fevers, high inflammatory markers, and raised liver function tests. She then developed an acute kidney injury and profound hypotension. She was treated with immunoglobulin for possible Kawasaki disease, broad spectrum antibiotics for possible toxic shock syndrome/ sepsis, and transferred to the regional PICU for ongoing inotropic support and management of her multi-system illness. She was found to have a non-dilated cardiomyopathy with poor left ventricular function, low complement and positive anti-streptolysin titres. No postive cultures or focus of infection were found. Antibody tests including dsDNA were negative. She required CPAP for respiratory support and was treated with pulsed methylprednisolone for systemic onset JIA. She then received a weaning course of prednisolone over several months and made an excellent recovery. Discussion: This was an interesting case for those involved because the initial symptoms, evolving signs and investigation results didn't easily tie together to give one suitable diagnosis. Several avenues of treatment were explored, including a range of antibiotics and immunoglobulin, before methylprednisolone. The patient also remained remarkably 'well' looking despite hermulti-organ impairment. Key learning points: This case highlighted the importance of awareness of systemic onset JIA and its complications, particularly in a non-typical age group, for the general paediatrician. Early discussion with and involvement of tertiary rheumatology services served to optimise management and outcome, and will hopefully also improve long-term prognosis.
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The authors have declared no conflicts of interest. Introduction: A case of adult-onset Still's disease initially diagnosed as lupus. A patient presented with clinical and immunological features consistent with SLE, however did not respond to conventional treatment. Over time she had recurrent flares associated with high inflammatory markers. Following extensive investigation she was diagnosed with adult-onset Still's disease. She remains well controlled on tocilizumab and methotrexate. This was significant, as the history and results of initial investigation were consistent with SLE. Adult-onset Still's disease was a diagnosis of exclusion following years of investigation. Diagnosis and an appropriate treatment regimen has resulted in prevention of further flares. Case description: A 49-year-old lady presented in 2011 with a history of joint pain, rash and fevers. Her inflammatory markers were raised, CRP of 267.7 mg/L, white cell count 14.8 Â 10 9 /L and neutrophil count 13.6 Â 109/L. ANA positive, with positive anti-RNP and anti-SM, dsDNA 73.3 IU/mL, pANCA positive, MPO 64. She was initially diagnosed with lupus. She was treated with multiple steroid sparing agents including mycophenolate mofetil, azathioprine and cyclophosphamide between 2011 and 2013. During this period she developed presumed cyclophosphamide-induced cardiomyopathy, and the cyclophosphamide was subsequently stopped. She has had recurrent flares presenting with rash and joint pain associated with raised inflammatory markers, neutrophilia and elevated ferritin, responding well to treatment with high dose steroids. During this time she has been extensively investigated for pyrexia of unknown origin. These investigations include two prior CT-PET scans in 2013 and 2015, which identified no source of sepsis or malignancy. Bone marrow aspirate performed 2015 demonstrated non-specific appearances with no malignancy. Symptomatic control was achieved for some time with methotrexate and low-dose steroids; however she had a significant flare and became acutely unwell witharash,feverandraised inflammatorymarkers,requiring admission to intensive care in 2017. During this flare, her white cell count was 28.1 Â 109/L, neutrophil count 26.4 Â 109/L, ferritin was 11741 ug/L. She 
